Maxim Positive on Omeros' (OMER) Omidria, OMS721; Reaffirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Omeros (OMER) Initiates Phase 3 for OMS721 Following FDA Meeting
March 8, 2016 7:03 AM ESTOmeros Corporation (NASDAQ: OMER) initiated its Phase 3 OMS721 program for the treatment of atypical hemolytic uremic syndrome (aHUS) after meeting with the U.S. Food and Drug Administration (FDA). OMS721 is Omeros lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies (TMAs), including aHUS. The FDA has awarded OMS721 both orphan drug designation for the treatment of TMAs and fast-track status for the treatment of aHUS.
The OMS721 Phase 3 program will consist of one clinical trial a single-arm (i.e., no control arm), open-label... More
Omeros (OMER) Tops Q4 Loss Per Share of 52c
March 7, 2016 5:26 PM ESTOmeros (NASDAQ: OMER) reported Q4 EPS of ($0.52), may not compare to analyst estimate of ($0.55). Revenue for the quarter came in at $6.66 million versus the consensus estimate of $5.35 million.
For earnings history and earnings-related data on Omeros (OMER) click here.
... More